ZCM
PDLI

Zebra Capital Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Zebra Capital Management’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-71,071
Closed -$207K – 315
2020
Q2 		$207K Sell
71,071
-2,879
-4% -$9.11K 0.3% 156
2020
Q1 		$208K Sell
73,950
-7,844
-10% -$25.3K 0.34% 137
2019
Q4 		$265K Buy
81,794
+7,884
+11% +$22.9K 0.24% 181
2019
Q3 		$160K Buy
73,910
+17,999
+32% +$48.1K 0.17% 198
2019
Q2 		$176K Buy
55,911
+25,934
+87% +$84.1K 0.09% 414
2019
Q1 		$112K Hold
29,977
– – 0.06% 413
2018
Q4 		$87K Sell
29,977
-44,718
-60% -$123K 0.05% 363
2018
Q3 		$196K Buy
74,695
+6,803
+10% +$16.7K 0.09% 385
2018
Q2 		$159K Sell
67,892
-47,539
-41% -$133K 0.07% 317
2018
Q1 		$339K Buy
115,431
+17,654
+18% +$48.2K 0.12% 278
2017
Q4 		$268K Sell
97,777
-12,041
-11% -$37K 0.09% 288
2017
Q3 		$372K Sell
109,818
-5,865
-5% -$16.3K 0.12% 226
2017
Q2 		$286K Sell
115,683
-11,088
-9% -$25.5K 0.09% 236
2017
Q1 		$288K Buy
126,771
+55,043
+77% +$122K 0.09% 249
2016
Q4 		$152K Sell
71,728
-7,861
-10% -$21.9K 0.05% 260
2016
Q3 		$267K Buy
79,589
+12,981
+19% +$41.2K 0.08% 256
2016
Q2 		$209K Buy
66,608
+16,410
+33% +$54.7K 0.07% 259
2016
Q1 		$167K Hold
50,198
– – 0.07% 247
2015
Q4 		$178K Sell
50,198
-5,496
-10% -$23K 0.1% 222
2015
Q3 		$280K Sell
55,694
-4,642
-8% -$26.6K 0.17% 216
2015
Q2 		$388K Buy
60,336
+11,368
+23% +$76.1K 0.23% 203
2015
Q1 		$344K Hold
48,968
– – 0.18% 199
2014
Q4 		$378K Buy
48,968
+20,121
+70% +$159K 0.15% 218
2014
Q3 		$215K Sell
28,847
-1,086
-4% -$10.1K 0.09% 237
2014
Q2 		$290K Buy
29,933
+13,348
+80% +$119K 0.11% 229
2014
Q1 		$138K Sell
16,585
-176,020
-91% -$1.51M 0.06% 278
2013
Q4 		$1.63M Buy
192,605
+40,448
+27% +$341K 0.85% 24
2013
Q3 		$1.21M Sell
152,157
-11,827
-7% -$95.1K 0.95% 17
2013
Q2 		$1.27M Buy
+163,984
New +$1.28M 1.05% 16

Other funds holding PDLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SPC
Silver Point Capital Greenwich, Connecticut $1.1B AUM 20.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Zebra Capital Management's PDLI Position: Q3 2020 in Review

Zebra Capital Management sold out of PDL BioPharma, Inc. (PDLI) in Q3 2020, closing a stake of 71,071 shares — an estimated $207K sold.

Zebra Capital Management first reported a position in PDLI in Q2 2013 and held it in 29 quarters. The position peaked at $1.63M in Q4 2013. 132 funds tracked by Wall St. Rank hold PDLI as of Q3 2020.

  • Zebra Capital Management reported no remaining PDL BioPharma, Inc. position as of Q3 2020 after selling out during the quarter.
  • Zebra Capital Management sold 71,071 PDL BioPharma, Inc. shares in Q3 2020, an estimated $207K.
  • Zebra Capital Management first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 29 quarters.
  • Zebra Capital Management's PDL BioPharma, Inc. position peaked at $1.63M in Q4 2013.
  • 132 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2020.

Based on Zebra Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.